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Abstract: The thioredoxin (Trx) system is an important enzyme family that regulates cellular
redox homeostasis. Protein expression of Trx system family members has been
assessed in various cancers and linked to various clinicopathological variables,
disease progression, treatment response and survival outcomes but information is
lacking in brain tumours. Expression of the system was therefore examined, by
immunohistochemistry in different brain tumour types, adult and paediatric cases, to
determine if expression was of importance to clinical outcome. Trx system proteins
were expressed, to variable levels, across all brain tumour types with significant
variations in expression between different tumour types/grades/regions. High Trx
reductase (TrxR) expression was linked to worse prognosis across all cohorts. High
cytoplasmic TrxR expression was significantly associated with adverse overall survival
(OS) in adult glioblastoma (P=0.027) and paediatric low-grade glioma (LGG) patients
(P=0.012). High expression of nuclear TrxR, cytoplasmic and nuclear Trx, and Trx-
interacting protein (TxNIP) was associated with improved OS in paediatric LGGs
(P=0.031, P<0.001, P=0.044, and P=0.018, respectively). For patients with high-grade
gliomas, both high cytoplasmic TrxR and Trx expression were associated with poor OS
(P=0.002 and P=0.007, respectively). In medulloblastoma, high expression of
cytoplasmic TrxR and Trx, and nuclear Trx was associated with worse prognosis
(P=0.013, P=0.033 and P=0.007, respectively); with cytoplasmic TrxR and nuclear Trx
remaining so in multivariate analysis (P=0.009 and P=0.013, respectively). The
consistent finding that high levels of cytoplasmic TrxR are associated with a worse
prognosis across all cohorts suggests that TrxR is an important therapeutic target in
brain cancers.
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The thioredoxin (Trx) system is an important enzyme family that regulates cellular redox homeostasis. Protein 
expression of Trx system family members has been assessed in various cancers and linked to various 
clinicopathological variables, disease progression, treatment response and survival outcomes but information is 
lacking in brain tumours. Expression of the system was therefore examined, by immunohistochemistry in different 
brain tumour types, adult and paediatric cases, to determine if expression was of importance to clinical outcome. 
Trx system proteins were expressed, to variable levels, across all brain tumour types with significant variations in 
expression between different tumour types/grades/regions. High Trx reductase (TrxR) expression was linked to 
worse prognosis across all cohorts. High cytoplasmic TrxR expression was significantly associated with adverse 
overall survival (OS) in adult glioblastoma (P=0.027) and paediatric low-grade glioma (LGG) patients (P=0.012). 
High expression of nuclear TrxR, cytoplasmic and nuclear Trx, and Trx-interacting protein (TxNIP) was 
associated with improved OS in paediatric LGGs (P=0.031, P<0.001, P=0.044, and P=0.018, respectively). For 
patients with high-grade gliomas, both high cytoplasmic TrxR and Trx expression were associated with poor OS 
(P=0.002 and P=0.007, respectively). In medulloblastoma, high expression of cytoplasmic TrxR and Trx, and 
nuclear Trx was associated with worse prognosis (P=0.013, P=0.033 and P=0.007, respectively); with 
cytoplasmic TrxR and nuclear Trx remaining so in multivariate analysis (P=0.009 and P=0.013, respectively). 
The consistent finding that high levels of cytoplasmic TrxR are associated with a worse prognosis across all 
cohorts suggests that TrxR is an important therapeutic target in brain cancers.  
Keywords: Thioredoxin, Thioredoxin Reductase, Glioblastoma, Low-grade glioma, High-grade glioma, 
Medulloblastoma 
Introduction 
Gliomas are the most frequent type of primary brain tumours in both adults and children, with glioblastoma 
multiforme (GBM) being the most malignant and most common type in adults [1]. Despite advances in diagnosis 
and treatment, survival times have not significantly improved for malignant glioma patients, especially GBM 
patients, whose median survival time is only around 15 months from diagnosis with a 5-year survival rate of 6% 
[2]. Medulloblastoma (MB) is the most frequent primary malignant brain tumour in children [3]. Based on clinical 
findings and histological subtype, MBs are currently categorised into two groups in clinical practice: average-risk 
and high-risk disease [4]. Although multimodal treatment strategies are used, 15-20% of the average-risk and 30-
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40% of the high-risk patients develop recurrences resulting in poor survival outcome [5]. The median survival 
after relapse is around 10 months [6] and the 5-year survival after relapse is 6% [7]. Collectively, both malignant 
gliomas and MBs are highly invasive tumours, with recurrence after treatment almost inevitable, resulting in 
extremely poor prognosis. There is, therefore, a pressing need to identify reliable and robust prognostic biomarkers 
to better stratify patients in order to improve their survival and to identify novel targets for development of 
therapeutics. 
Redox homeostasis is often disrupted in cancer cells due to increased oxidative stress caused by the accelerated 
proliferation, high metabolic rate and persistent growth promoting signalling pathways of tumours [8]. To 
maintain the redox balance, antioxidant systems such as the thioredoxin (Trx) system are often 
deregulated/overexpressed in aggressive tumours to counteract the increased oxidative stress [9]. The Trx system 
is a key antioxidant pathway in defence against oxidative stress and comprises Trx reductase (TrxR), its ubiquitous 
substrate Trx and the endogenous inhibitor of this system - Trx-interacting protein (TxNIP) [10]. TrxR reduces 
oxidised disulfide-containing Trx back to its biologically active dithiol form in a NADPH-dependent manner and 
the reduced Trx, in turn, reduces oxidised cysteine groups on down-stream proteins [11]. TxNIP inhibits Trx 
activity and its interactions with downstream factors by directly binding to the catalytic centre of Trx [12]. The 
Trx system plays a key role in maintaining redox-regulated cellular functions including transcription, DNA 
damage recognition and repair, proliferation and apoptosis [13,11].  
The Trx system proteins are deregulated/overexpressed in a number of different cancers with the level of 
expression often associated with tumour aggressiveness, metastasis, prognosis, and treatment responses [14-
17,9,18]. There is very little information regarding the association of this system with clinicopathological factors 
and prognosis in brain tumours, especially paediatric gliomas and medulloblastomas. Jarvela et al. indicated that 
increased Trx expression was associated with higher tumour grade and poor prognosis in oligodendrogliomas [19]. 
Haapasalo et al. found a positive association between the expression of Trx/TrxR and tumour grade in 
astrocytomas with only high Trx expression significantly associated with poor prognosis [20]. The levels of TrxR 
in GBM patients were shown to be higher than in normal brain tissue, indicating that TrxR may be related to the 
progression of GBM [21]. In a recent study, low TxNIP expression in glioma was associated with higher 
histological grade and shorter patient survival [22].  
Although the role of Trx system has been studied in malignant gliomas, few studies have assessed the prognostic 
value of this Trx system as a whole across a variety of brain tumour types and there have been no studies conducted 
in paediatric patients. The aim of the current study was, therefore, to use immunohistochemical approaches to 
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assess the expression of all three members of the Trx system in four different brain tumour cohorts, to evaluate 
their associations with clinicopathological and survival criteria, and additionally to compare levels of expression 
across different tumour regions/types/grades. 
Material and methods 
Clinical samples 
This study is reported in accordance with REMARK (reporting recommendations for tumour marker prognostic 
studies) criteria [23]. Ethical approval was granted by Local Regional Ethics Committee in Nottingham, under the 
title ‘Comparative molecular analysis of childhood brain tumours’ (11/EM/0076; R&I 14CS005). Four 
independent cohorts were used in this study: adult GBM, paediatric low-grade glioma (LGG) (WHO grade I and 
II), paediatric high-grade glioma (HGG) (WHO grade III and IV) and MB cohorts. A total of 395 primary brain 
tumour patients were diagnosed and treated at various hospitals across England (mainly Nottingham and 
Birmingham) between 1970 and 2015. Exclusion of referral, miscoded, and recurrent cases resulted in 302 cases 
with available clinical information. The clinicopathological variables of the cohorts are listed in Supplementary 
Table 1-3. Overall survival time was calculated from the date of original diagnosis to death or from date of original 
diagnosis to last date known to be alive for those censored. 
The 18 cases in the adult GBM cohort were treated at Nottingham University Hospitals between 2013 and 2015. 
The median age for this cohort was 59 years (ranging from 26 to 73). The median follow-up time was 15 months 
(ranging 1-42). Patients were managed under a uniform protocol, where all underwent complete (14/18) or partial 
resection (4/18), as decided by disease characteristics. The majority of the patients (16/18) completed 60 Gray (2 
Gray per fraction over 6 weeks) radiotherapy and adjuvant temozolomide treatment whilst the remaining 2 patients 
only received radiotherapy. 
The 126 paediatric patients in the LGG cohort were treated at various hospitals in England between 1970 and 
2003. The median age for this cohort was 6 years (ranging from 3 months to 16 years) and 81% of patients had 
grade I disease (92/114); where patient number did not total 126, information was not available for the remaining 
patients. The median follow-up time was 168 months (ranging 0-416). Unfortunately, surgical and adjuvant 
treatment data were not available for this cohort. 
The paediatric HGG cohort included 137 patients who were diagnosed at various hospitals in England between 
1982 and 2007. The median follow-up time was 12 months (ranging 0-206). 26.7% of patients had grade III 
tumours (35/131) and 73.3% of patients had grade IV tumours (96/131). 15.8% of patients had complete tumour 
5 
 
resection (16/101), 43.6% of patients had partial resection (44/101), and 40.6% of patients had biopsies (41/101). 
Where patient number did not total 137 information was not available for the remaining patients. The adjuvant 
treatment data for this cohort were also not available. 
In the MB cohort, 114 patients were diagnosed and treated at Birmingham and Nottingham University Hospitals 
between 1985 and 2012. The median follow-up time was 53 months (ranging 1-249). The median age of the 
patients was 7 years (ranging from 9 months to 19 years). According to conventional histological classification, 
61.3% of patients were classified as classic MB (57/93), 16.1% as desmoplastic MB (15/93), 17.2% as large 
cell/anaplastic MB (16/93), 1.1% as MB with extensive nodularity (1/93) and 4.3% as MB with myogenic 
differentiation (4/93). The metastatic stage of MBs was determined according to the Modified Chang Staging 
System [24], where the extent of metastasis is subdivided into M0 (no metastasis), M1 (presence of tumours in 
the cerebrospinal fluid), M2 (gross nodular seeding present intracranially beyond the primary tumour site), M3 
(metastasis in spinal subarachnoid space), and M4 (metastases outside the cerebrospinal axis). Among the 92 
patients with available metastatic information, 60.9% of patients were M0 stage (56/92), 6.5% of patients were 
M1 stage (6/92), 10.9% of patients were M2 stage (10/92), 18.5% of patients were M3 stage (17/92), and 3.3% of 
patients were M4 stage (3/92). As with the paediatric LGG and HGG cohorts, the treatment details were also not 
available for this cohort. 
Tissue microarray and immunohistochemistry  
Protein expression was assessed using freshly cut 4 μm sections from tissue microarrays (TMAs). TMAs were 
kindly provided to the current authors by Prof. Richard Grundy and Mr Stuart Smith from the Children’s Brain 
Tumour Research Centre, the University of Nottingham, UK. For paediatric LGG, HGG and MB TMAs, two/three 
0.6 mm tissue cores were used for each patient. Adult GBM TMAs were constructed as described previously [25]. 
In short, triplicate cores were collected from each of three regions (inner tumour core, rim and invasive margin) 
per tumour specimen. 
Following optimisations immunohistochemistry (IHC) was performed as previously described using a Novolink 
Polymer Detection Kit (Leica) according to the manufacturers’ instructions [26]. Briefly, slides were dewaxed in 
xylene and rehydrated in industrial methylated spirit (IMS), followed by antigen retrieval in 0.01 M sodium citrate 
buffer (pH 6.0) in a microwave for 20 min, with 10 min at 750W and 10 min at 450W. Tissue was treated with 
peroxidase block for 5 min, washed with Tris-buffered saline (TBS), and then treated with protein block solution 
for another 5 min at room temperature. Primary antibodies against Trx (1:2000, Abcam), TrxR (1:150, Abcam) 
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and TxNIP (1:1000, Abcam) were incubated on tissue overnight at 4 °C, with antibody specificity initially 
confirmed by Western blotting (Supplementary Fig. 1). Following antibody incubation, tissues were washed with 
TBS and incubated with post primary solution, then washed and incubated with Novolink polymer solution. 
Immunohistochemical reactions were visualised using 3, 3’-diaminobenzidine and counterstained with 
haematoxylin. Slides were then dehydrated in IMS, fixed in xylene before mounting with DPX. Controls were 
included with each run: breast tumour composite sections, comprised of grade 1 and 2 early stage invasive tumours, 
were included as positive controls, with negative controls omitting primary antibody. 
Assessment of expression 
Staining was assessed at 200x magnification following high-resolution scanning (Nanozoomer Digital Pathology 
Scanner, Hamamatsu Photonics). Assessment was conducted with involvement and training provided by a 
consultant neuropathologist (SP). Cytoplasmic staining was semi-quantitatively assessed using an 
immunohistochemical H-score [27]; where staining intensity was assessed as none (0), weak (1), medium (2), or 
strong (3) over the percentage area of each staining intensity. Nuclear staining was assessed as the percentage of 
nuclei with any intensity of staining. 30% of cores for each protein were examined by a second independent 
assessor blinded to clinical outcome and the primary assessor’s scores. Good concordance was demonstrated 
between scorers (single measure intraclass correlation coefficients were above 0.7 for all markers assessed across 
all brain tumour cohorts) (Supplementary Table 4). Unbiased cut-points, for stratification, were obtained based 
on overall survival using X-tile software [28].  
Statistical analysis 
Data analysis was performed using SPSS 24.0 software. The relationships between categorised protein expression 
and clinicopathological variables were examined using Pearson’s χ2 test of association or Fisher’s exact test if a 
cell count was less than 5 in a 2×2 table. Kaplan-Meier survival curves were plotted with significance determined 
using the Log-rank test. The Cox proportional hazards regression model was used in multivariate survival analysis. 
The differences in protein expression between different tumour types/grades/regions were determined using one-
way ANOVA or non-parametric Kruskal-Wallis test when the homogeneity of variance was violated. Multiple 
comparisons between two groups were conducted using a pairwise post-hoc t-test or Mann-Whitney U test when 




Expression pattern of Trx system in brain tumours 
TrxR, Trx and TxNIP expression displayed a mixture of diffuse and granular cytoplasmic staining in all types of 
brain tumours. Some diffuse nuclear staining was also observed for TrxR and Trx. Representative staining patterns 
are shown in Fig. 1. Heterogeneous staining was shown between, as well as within, certain tumour cores for all 
markers, varying from weak to intense. Occasional stromal and endothelial cell staining was also observed; 
however, this was not scored as part of this study. The median scores and ranges of TrxR, Trx and TxNIP 
expression for each tumour cohort are shown in Supplementary Table 5 with X-tile cut-off points listed in 
Supplementary Table 6. TMA cores with insufficient tumour cells (<15%) were not scored or included in the 
analysis.  
Relationship of Trx system expression with clinicopathological variables and clinical outcome in the adult 
GBM cohort. 
In the adult GBM cohort, the relationships between Trx system protein expression and clinicopathological 
variables were independently assessed by tumour region (i.e. core, rim, and invasive margin). In core samples, 
high nuclear TrxR expression was associated with tumours located at temporal lobe (χ2=9.370, df=3, P=0.008); 
in samples taken from the invasive margin, high cytoplasmic TrxR expression was also linked with male patients 
(χ2=8.571, df=1, P=0.015) (Supplementary Table 7). No significant associations between Trx or TxNIP expression 
and clinicopathological variables were observed in any tumour regions (data not shown). 
In rim samples high cytoplasmic TrxR expression was significantly associated with adverse overall survival 
(P=0.027) whereas nuclear TrxR expression was not (P=0.462) (Fig. 2a and b). The expression of 
cytoplasmic/nuclear Trx and TxNIP was also not associated with overall survival (P=0.147, 0.752 and 0.977, 
respectively) (Fig. 2c-e). No associations were observed between TrxR, Trx and TxNIP expression and overall 
survival in either core or invasive samples (data not shown). In addition, none of the traditional prognostic 
variables including patient age, tumour site, resection status and IDH-1 status was associated with patient survival 
(with individual Kaplan-Meier statistics of P=0.396, P=0.484, P=0.855, and P=0.643 respectively). Therefore, 
multivariate analysis was not performed to determine whether cytoplasmic TrxR had independent prognostic 
value in rim samples. 
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Relationship of Trx system expression with clinicopathological variables and clinical outcome in the 
paediatric LGG cohort. 
In the paediatric LGGs, high cytoplasmic TrxR was associated with supratentorial tumours (χ2=10.384, df=1, 
P=0.002) and the presence of tumour recurrence (χ2=10.231, df=1, P=0.004), whereas high nuclear TrxR 
expression was associated with the absence of tumour recurrence (χ2=9.850, df=1, P=0.001). High expression of 
both cytoplasmic Trx and TxNIP was also associated with the absence of tumour recurrence (χ2=5.663, df=1, 
P=0.029 and χ2=6.147, df=1, P=0.013, respectively). The expression of nuclear Trx was not significantly 
associated with any of the clinicopathological variables (Supplementary Table 8 and Table 9). 
Kaplan-Meier survival analysis showed that high expression of cytoplasmic TrxR was significantly associated 
with poor overall survival (P=0.012) (Fig. 3a) whereas high TrxR expression in the nucleus was associated with 
improved overall survival (P=0.031) (Fig. 3b). High expression of Trx within both cytoplasm and nucleus was 
significantly associated with improved overall survival (P<0.001 and P=0.044, respectively) (Fig. 3c and d). In 
addition, high TxNIP expression was also associated with improved overall survival (P=0.018) (Fig. 3e). The 
multivariate analysis was also not performed in this cohort as none of the potential confounding factors were 
significantly associated with patient survival including tumour grade, tumour site, patient age, and gender (with 
individual Kaplan-Meier statistics of P=0.058, P=0.284, P=0.613, and P=0.939, respectively). 
Relationship of Trx system expression with clinicopathological variables and clinical outcome in the 
paediatric HGG cohort. 
In the paediatric HGGs, anaplastic oligodendroglioma was significantly associated with high cytoplasmic Trx 
expression whilst GBM with low expression (χ2=9.785, df=2, P=0.008). High cytoplasmic TxNIP expression was 
linked with GBM (χ2=9.362, df=2, P=0.009), supratentorial tumours (χ2=5.314, df=2, P=0.021) and higher tumour 
grade (χ2=7.923, df=1, P=0.005) (Supplementary Table 10). No associations between both cytoplasmic and 
nuclear TrxR expression and clinicopathological variables were observed (data not shown). 
Univariate survival analysis showed that high expression of both cytoplasmic TrxR and Trx was significantly 
associated with adverse overall survival (P=0.002 and P=0.007, respectively) (Fig. 4a and c), while expression of 
both TrxR and Trx in the nucleus was not significantly associated with overall survival (P=0.084 and P=0.482 
respectively) (Fig. 4b and d). No association was detected between TxNIP expression and overall survival 
(P=0.181) (Fig. 4e). Again, multivariate analysis could not be conducted as none of the potential confounding 
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factors, namely age at diagnosis, gender, histological subtypes, tumour grade, tumour site and extent of surgery, 
were found to be significantly associated with survival in univariate analysis (with individual Kaplan–Meier 
statistics of P=0.224, P=0.949, P=0.211, P=0.085, P=0.688, and P=0.494, respectively).  
Relationship of Trx system expression with clinicopathological variables and clinical outcome in the 
paediatric MB cohort. 
In MBs, high expression of both cytoplasmic and nuclear Trx was associated with the presence of tumour 
recurrence (χ2=4.655, df=1, P=0.031 and χ2=5.851, df=1, P=0.016, respectively). High nuclear Trx expression 
was also linked with extensive nodularity subtype whilst low expression with classic subtype (χ2=9.941, df=4, 
P=0.041) (Supplementary Table 11). No other significant associations were found between protein expression 
and clinicopathological variables (data not shown). 
As with the other cohorts patients with high cytoplasmic TrxR expression had significantly shorter overall survival 
compared with low expression (P=0.013) (Fig. 5a). High Trx expression within cytoplasm and nucleus were both 
associated with adverse overall survival (P=0.033 and P=0.007, respectively) (Fig. 5c and d). No significance was 
observed between nuclear TrxR or TxNIP expression and overall survival (P= 0.230 and P= 0.287, respectively) 
(Fig. 5b and e). In multivariate Cox regression analysis, cytoplasmic TrxR and nuclear Trx expression both 
remained significantly associated (P=0.009 and 0.013, respectively) with overall survival when including the 
potential confounding factors of age, extent of surgery and metastatic status in the analysis (with individual 
Kaplan–Meier statistics of P=0.001, P=0.038, and P<0.001, respectively), whereas cytoplasmic Trx expression 
was not independently associated with survival (P=0.206) (Table 1). 
Comparison of protein expression between different regions in adult GBM  
As shown in Fig. 6a, the levels of cytoplasmic TrxR expression significantly differed between the core, rim and 
invasive regions of adult GBM tumours (P=0.043). On a post-hoc t-test, there was a significantly higher level of 
cytoplasmic TrxR in the rim region than the invasive region (P=0.036), but there were no significant differences 
between core and rim (P=0.713) or core and invasive regions (P=0.190). A significant difference in nuclear TrxR 
expression was also observed between these three intra-tumour regions (P=0.003). On post-hoc t-test, there was 
a significant difference between core and rim samples (P=0.019), and between core and invasive samples 
(P=0.004), but not between rim and invasive samples (P=0.724) (Fig. 6b). The expression levels of 
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cytoplasmic/nuclear Trx and TxNIP were also compared between different GBM areas, but no statistically 
significant variations were detected (P=0.987, 0.442 and 0.944, respectively) (Fig. 6c-e). 
Comparison of protein expression between different tumour types  
There was a significant difference in cytoplasmic TrxR expression between adult GBMs, paediatric LGGs, 
paediatric HGGs, and MBs (P<0.001) (Fig. 7a). From the post-hoc t-test, the significant differences were observed 
between paediatric LGGs and HGGs (P<0.001), and between paediatric HGGs and MBs (P<0.001), whereas no 
significant differences were detected between adult GBM and any of the other three tumour types. Statistically 
significant variations of nuclear TrxR expression were also observed between these four brain tumour types 
(P<0.001), with significant differences detected between paediatric LGGs and HGGs (P<0.001) and between 
paediatric HGGs and MBs (P<0.001) (Fig. 7b). 
There was a significant difference in cytoplasmic Trx expression between different types of brain tumours 
(P=0.003) and the difference between paediatric LGGs and MBs was the only pair that achieved statistical 
significance (P=0.004) (Fig. 7c). Significant differences in nuclear Trx expression were also found between 
different brain tumour types (P<0.001) (Fig. 7d). MBs showed significantly higher levels of nuclear Trx 
expression, relative to both the paediatric LGGs (P=0.011) and HGGs (P<0.001); and paediatric HGGs displayed 
significantly greater levels of such expression than the paediatric LGGs (P=0.027).  
The levels of TxNIP expression also differed between different tumour types (P=0.017). Median TxNIP 
expression was highest for the paediatric HGGs (188, range 10-280), followed by adult GBMs (175, range 45-
228), paediatric LGGs (173, range 0-280), and lowest for MBs (150, range 12-270) (Fig. 7e). There were 
significant differences between paediatric LGGs and HGGs (P=0.022), and between paediatric HGGs and MBs 
(P=0.004). 
Comparison of protein expression between different tumour grades in paediatric gliomas 
In total, there were 159 valid cases of paediatric gliomas including 82 grade I, 25 grade III, and 52 grade IV 
gliomas. Unfortunately, the grade II gliomas were not included in this analysis, as scoring was not able to be 
conducted due to missing cores or insufficient tumour tissues. As shown in Supplementary Fig. 2a, the expression 
of cytoplasmic TrxR was significantly higher in grade I gliomas than both grade III (P=0.010) and grade IV 
gliomas (P=0.001). Like cytoplasmic TrxR expression, grade I gliomas also showed the highest level of nuclear 
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TrxR expression whilst the grade III gliomas had the lowest level (Supplementary Fig. 2b). A significant 
difference in nuclear TrxR expression was observed between grade I and grade IV gliomas (P=0.001), but not 
between grade I and III (P=0.085) or between grade III and IV gliomas (P=0.974).   
The expression levels of cytoplasmic Trx were nearly equal between grade I, III, and IV gliomas with median 
values of H-scores ranging from 92 to 101 (P=0.876) (Supplementary Fig. 2c). Nuclear Trx expression was 
elevated in both the grade III and grade IV gliomas compared with grade I’s but this did not achieve statistical 
significance (P=0.448) (Supplementary Fig. 2d). As shown in Supplementary Fig. 2e, TxNIP expression increased 
as pathological grades increased, with the expression being significantly higher in grade IV than in grade I gliomas 
(P=0.001), but no difference was noted between grade I and III (P=0.556) or between grade III and IV gliomas 
(P=0.052). 
Discussion  
The current study investigated the expression of all three Trx system proteins in four independent brain tumour 
cohorts (i.e. adult GBM, paediatric LGG, paediatric HGG, and MB); and whether any associations existed 
between their expression and patient prognosis or with clinicopathological variables. The difference in the levels 
of Trx system protein expression between different tumour regions/types/grades was also investigated. This is the 
first study to report upon the expression of all three members of Trx system proteins together in such a broad 
variety of brain tumour types and to evaluate their prognostic values. 
The Trx system is a key member of the cellular systems responsible for regulating redox homeostasis. Protein 
overexpression of Trx system members has been demonstrated in many human cancers with expression often 
associated with increased tumour progression and worse patient prognosis. Although there are a few studies that 
have investigated Trx system protein expression in GBMs, none have assessed prognostic importance with this 
being the first study to examine expression of all three members of the system together in adult GBM patients and 
to evaluate their prognostic significance. Current survival data demonstrate that high cytoplasmic TrxR expression 
is significantly associated with adverse overall survival in adult GBMs (rim area) (P=0.027). In a study of 27 
GBM cases, Kemerdere et al. [21] reported that serum and tissues levels of TrxR were increased in GBM patients, 
but this study did not assess associations with patient survival. A study investigating 40 GBM patients showed 
significantly higher TrxR expression in primary GBMs with TrxR expression highly correlating with the Ki-67 
index, but the study also did not assess for associations with patient survival [29]. A further study assessed TrxR 
in 20 GBM patients, showing higher TrxR expression in GBMs containing intratumoural haemorrhage, suggesting 
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a role for TrxR in the promotion of tumour angiogenesis and growth, but again associations with patient survival 
were not presented [30]. The number of adult GBM patients included in the current study (n=18) could be regarded 
as being rather small however the low incidence of this tumour type should be borne in mind. The standardised 
incidence of GBM in England is only ~5 per 100,000 persons per year [31]. The patient number in this study 
compares well against others that have sought to examine Trx system in GBM i.e. the studies from Kaya et al. 
[30] and Kemerdere et al. [21] which included 20 and 27 GBM patients, respectively.  
Molecular studies have shown that different regions of GBM tumours have different profiles of molecular 
abnormalities and differing expression profiles for known tumour markers [25]. This study assessed and compared 
the diversity of Trx system protein expression across distinct intra-tumour regions of adult GBM with results 
revealing that the rim region had the highest cytoplasmic TrxR expression as compared to the other two regions 
and that the rim and invasive margin expressed higher nuclear TrxR than the core region. Such results indicate 
that TrxR is overexpressed in periphery tumour regions, suggesting that such overexpression may be linked to 
GBM invasiveness and migration. It should be remembered, however, that this cohort is relatively small (n=18) 
and homogeneous, and that results were obtained using a TMA, which may be not representative of the whole 
tissue section, especially for antigens with heterogeneous staining patterns in tumours [32]. Thus, further studies 
with a larger population are recommended, to evaluate the validity and reliability of using TMA to assess TrxR 
expression in adult GBMs, by analysing the concordance between data obtained from TMAs and whole mount 
sections. 
The Trx system in LGG is understudied and poorly understood, with only very few studies assessing clinical 
importance and with none including paediatric patients. One study, investigating the prognostic significance in 
grade I pilocytic astrocytomas (n=42), found no associations between TrxR or Trx expression and 
clinicopathological or survival criteria [20]. On the contrary, significant associations were seen in the current 
study, results showing that high cytoplasmic TrxR expression was significantly associated with tumour recurrence 
and adverse overall survival (P=0.012); and with high nuclear TrxR expression associated with lower risk of 
recurrence and improved overall survival (P=0.031). Such findings are similar to results obtained in a breast 
cancer study by our group [33], i.e. a high nuclear expression of TrxR was associated with better overall survival. 
The different results between cytoplasmic and nuclear TrxR may be due to the subcellular localisation of TrxR 
that can influence its function within the cell and therefore its involvement in the carcinogenic process and/or 
prediction of clinical outcome. Another study investigating 85 oligodendrogliomas showed that high Trx 
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expression was associated with poor prognosis in univariate analysis (P=0.0343) and remained significant in 
multivariate analysis (P=0.009) [19]. This is in contrast to the current study that shows that Trx is a good 
prognostic factor in paediatric LGG. Differences may be due to a number of factors including study populations. 
The LGG cohort in the current study mainly consisted of grade I pilocytic astrocytomas from paediatric patients, 
while the study from Jarvela et al. included both grade II and III oligodendrogliomas. Besides, the different forms 
of Trx may also contribute to the disagreement, as the immunohistochemical technique and the antibodies that are 
currently available cannot discriminate the oxidized and reduced forms of the protein in archival material [34]. 
Apart from Trx, high TxNIP expression was also a prognostic factor for better overall survival in this cohort, 
which is consistent with a study conducted in locally advanced breast cancer patients [9].  
Limited studies have investigated protein expression of the Trx system in HGGs with no known reports previously 
conducted in paediatric tumours. Haapasalo et al. [20] demonstrated that Trx expression was associated with 
worse prognosis in diffuse astrocytomas (n=391) and Trx was an independent prognostic factor in addition to 
histology and proliferation. In primary human gastric cancers high levels of Trx expression also correlated with 
shorter patient survival [15]. Consistent with these findings, the current study shows that cytoplasmic Trx 
expression associates with poor prognosis in HGGs. In a previous study of 54 glioma patients (29 LGGs and 25 
HGGs), high TxNIP expression associated with extended patient survival [22], however, no association was 
observed between TxNIP and survival of HGG patients in the current study. 
In the MB cohort, high expression of cytoplasmic/nuclear Trx (P=0.033 and P=0.007, respectively) and 
cytoplasmic TrxR (P=0.01) significantly associated with adverse overall survival; and except for cytoplasmic Trx 
remained so in multivariate analysis. Such results indicate the importance of the Trx system in MB progression 
and the potential of using assessment of Trx system protein expression to predict clinical outcome. This is the first 
study to examine the expression of Trx system in MB and report on its significance in respect to patient survival. 
There are no previous studies investigating the role of the Trx system in MB patients or cell lines. Additional 
clinical studies with larger patient numbers are warranted to validate these findings.  
Apart from the exploration of the relationship between protein expression and clinicopathological and survival 
criteria, the current study also compared levels of Trx system proteins across different brain tumour types with 
results revealing significant variations in expression. Interestingly MBs are more likely to show increased TrxR 
and Trx expression, and decreased TxNIP expression, which may confer a more aggressive behaviour. Although 
the adult GBMs showed some increased/decreased protein expression compared to the paediatric tumours, no 
significance was achieved, perhaps due to the small sample size of the adult GBM cohort (n=18). A larger study, 
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including more adult cases, could determine if variation in protein expression exists between adult and paediatric 
tumours. 
Due to the observed difference in expression across different brain tumour types, it was of interest to see if there 
was an association between expression and grade. A significantly higher expression of both cytoplasmic and 
nuclear TrxR was observed in grade I gliomas, and the grade IV gliomas had the highest TxNIP expression; 
whereas no significant variation in Trx expression was noted between different grades. These results are, perhaps, 
unexpected as previous data in gliomas often find that high levels of TrxR/Trx or low levels of TxNIP are 
associated with increased tumour grade. Haapasalo et al. [20] reported that grade II-IV astrocytomas (diffuse 
astrocytomas) showed more intense staining by TrxR and Trx than grade I astrocytomas, and within diffuse 
astrocytomas, TrxR and Trx showed significantly increasing expression with the malignancy grade. Esen et al. 
[35] found that grade I-IV astrocytomas showed significantly higher TrxR expression when compared with their 
normal tissues counterparts and TrxR was overexpressed according to the ascending tumour grade. Recently, Trx 
expression was also reported to increase with glioma grade [36]. In line with this, marked downregulation of 
TxNIP in HGGs was demonstrated as compared with LGGs [22]. The discordant results between the current and 
previous studies could be due to a number of factors including study populations, antibodies used, sample sizes, 
methodological problems, and other potential confounding factors. It should be noted that the samples in the 
current study were all from paediatric patients, and the others mainly focused on adult samples. Histologically, 
adult and childhood brain tumours are usually similar, but they differ dramatically in their genetic and epigenetic 
profiles. 
This current study used four independent brain tumour cohorts including both adult and paediatric patients to 
demonstrate associations between the expression of the Trx system and clinicopathological or survival criteria. 
Although some mixed results were observed between different cohorts, there was a consistent finding that high 
levels of cytoplasmic TrxR equated with a worse prognosis across all cohorts, supporting the prognostic value for 
determination of TrxR expression in different brain tumour types. The majority of the studies to date have assessed 
only one or maximum two members of the Trx system in focused brain tumour populations. However, the current 
study took a further step to examine a panel of all three members of the Trx system in a wide range of brain tumour 
types. Among these three members, TxNIP seemed to be the least useful marker to predict prognosis. In addition, 
the current study also demonstrated differential protein expression of Trx system between brain tumour types, 
between tumour grades, and between intra-tumour regions, which perhaps indicates the complex and 
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heterogeneous features of brain tumours and the high levels of inter-tumour and intra-tumour heterogeneity may 
hinder accurate diagnosis and effective treatment. 
Although the present study offers several strengths, there are also some limitations. For example for certain 
cohorts some important clinical data (e.g. adjuvant treatment details) was unavailable, due to the age of certain 
study populations in terms of dates when patients presented i.e. non-electronic records being kept at the time with 
challenges facing data retrieval across national locations. Also, a proportion of cores within the TMAs could not 
be assessed due to missing tissue, cancer necrosis, or insufficient cancer cells, which reduced the number of cases 
that could be used for statistical analyses. In addition, the sample size of the cohorts, particularly the adult GBM 
cohort, was relatively small (n=18), but even so, with the interesting results obtained, further investigation of these 
observations in larger cohorts are warranted. Although MB is historically considered as a single disease, it is now 
widely accepted that it comprises 4 distinct subgroups (i.e. WNT, SHH, group 3, and group 4) that have prognostic 
significance, based on their DNA methylation profiling. Unfortunately, such methylation information is not 
included in this study as advances in molecular testing, to allow sub-grouping, was not available at the time of 
presentation. In addition, the relatively small sample size (n=114) might be problematic if subgrouping was 
conducted. Based upon the interesting data obtained, further studies are warranted, with larger numbers of patients 
(more contemporary, with molecular characterisation and with full treatment data), to allow subgroup analysis to 
be conducted.   
In conclusion, this study shows that Trx system proteins, namely TrxR, Trx and TxNIP, are widely expressed 
across a variety of brain tumour types with high cytoplasmic TrxR expression consistently associating with worse 
prognosis in all brain tumour types, suggesting that TrxR is a potentially important therapeutic target in brain 
cancers. 
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Fig. 1 Representative photomicrographs of Trx system expression in different brain tumour types. Examples of 
TrxR (left panel), Trx (middle panel), and TxNIP (right panel) staining in (a-c) adult glioblastoma; d-f paediatric 
low-grade glioma; g-i paediatric high-grade glioma; j-l paediatric medulloblastoma; m representative positive 
control of TrxR on breast cancer tissue; n representative negative control with omission of the primary antibody 
on breast cancer tissue. Images were taken at 10x magnification with 20x magnification inset panel. Scale bar 
represents 100 μm 
Fig. 2 Kaplan-Meier overall survival curves in the adult GBM cohort (rim). a High expression of cytoplasmic 
TrxR is associated with poor overall survival (P=0.027). No significant associations between nuclear TrxR (b), 
cytoplasmic/nuclear Trx (c/d) or TxNIP (e) expression and overall survival are observed (all P values >0.05). 
Curves show low (blue line) and high protein expression (green line) with significance determined using the log-
rank test. The numbers below the Kaplan-Meier curves are the number of patients at risk at the specified month 
Fig. 3 Kaplan-Meier overall survival curves in the paediatric LGG cohort. a High expression of cytoplasmic TrxR 
is associated with adverse overall survival (P=0.012) whilst high expression of nuclear TrxR (b) is correlated with 
better overall survival (P=0.031). High expression of cytoplasmic (c) or nuclear (d) Trx is associated with 
improved overall survival (P<0.001 and P=0.044, respectively). e High expression of TxNIP is also associated 
with better overall survival (P=0.018). Curves show low (blue line) and high protein expression (green line) with 
significance determined using the log-rank test. The numbers below the Kaplan-Meier curve are the number of 
patients at risk at the specified month 
Fig. 4 Kaplan-Meier overall survival curves in the paediatric HGG cohort. High expression of cytoplasmic TrxR 
(a) and Trx (c) is associated with adverse overall survival (P=0.002 and P=0.007, respectively). No significant 
associations are found between the expression of nuclear TrxR (b), nuclear Trx (d), or TxNIP (e) and overall 
survival (P=0.084, 0.482 and 0.181, respectively). Curves show low (blue line) and high protein expression (green 
line) with significance determined using the log-rank test. The numbers below the Kaplan-Meier curves are the 
number of patients at risk at the specified month 
Fig. 5 Kaplan-Meier overall survival curves in the MB cohort. High expression of cytoplasmic TrxR (a), 
cytoplasmic Trx (c) and nuclear Trx (d) is associated with adverse overall survival (P=0.013, P=0.033 and 
P=0.007, respectively). No significance is observed between nuclear TrxR (b) or TxNIP (e) expression and overall 
survival (P= 0.230 and P= 0.287, respectively). Curves show low (blue line) and high protein expression (green 
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line) with significance determined using the log-rank test. The numbers below the Kaplan-Meier curve are the 
number of patients at risk at the specified month 
Fig. 6 Box plots of protein expression in different regions of adult GBM tumours. (a) A significantly higher 
expression of cytoplasmic TrxR is noted in the rim samples compared to the invasive samples (P=0.036 on post-
hoc t-test). (b) Significant differences in nuclear TrxR expression were observed between core and rim regions 
(P=0.019) and between core and invasive regions (P=0.004) but not between rim and invasive regions (P=0.724). 
No statistically significant variations are detected between areas for cytoplasmic or nuclear Trx (c and d, 
respectively) or TxNIP expression (e). * represents P<0.05, ** represents P<0.01 
Fig. 7 Box plots of protein expression in different brain tumour types. The expression of both cytoplasmic (a) and 
nuclear (b) TrxR is significantly lower in pHGG than pLGG and MB (P<0.001). Cytoplasmic Trx (c) expression 
is significantly higher in MB compared to pLGG (P=0.004), and nuclear Trx (d) expression significantly differs 
between pLGG, pHGG and MB (P<0.001), with pLGG having the lowest level and MB having the highest level. 
(e) A significantly higher expression of TxNIP is noted in pHGG compared to pLGG and MB (P=0.017). * 
represents P<0.05, ** represents P<0.01, *** represents P<0.001 
Table 1 Multivariate Cox proportional hazards analysis for predictors of overall survival in 
medulloblastoma patients. 
Variables P value Exp (B) 
95% CI for Exp(B) 
Lower Upper 
Cytoplasmic TrxR expression 0.009 4.850 1.487 15.822 
Age (3 years) 0.004 0.190 0.062 0.585 
Extent of surgery 0.397 0.643 0.232 1.785 
Metastatic status 0.000 6.354 2.266 17.816 
Cytoplasmic Trx expression 0.206 1.895 0.703 5.107 
Age (3 years) 0.007 0.221 0.074 0.662 
Extent of surgery 0.549 0.716 0.240 2.132 
Metastatic status 0.003 5.640 1.812 17.555 
Nuclear Trx expression 0.013 5.386 1.418 20.451 
Age (3 years) 0.003 0.188 0.062 0.572 
Extent of surgery 0.097 0.311 0.079 1.233 
Metastatic status 0.011 4.033 1.375 11.827 
Significant P values are indicated by bold type. Exp(B) is used to denote hazard ratio and 95% CI is used to denote 
95% confidence interval. 
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